



## Ardelyx to Present at the H.C. Wainwright 25th Annual Global Investment Conference

September 8, 2023

WALTHAM, Mass., Sept. 08, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that Mike Raab, president and chief executive officer of Ardelyx, will present at the H.C. Wainwright 25<sup>th</sup> Annual Global Investment Conference on Monday, September 11, 2023, at 12:00 p.m. ET in New York City.

To access the live webcast of Ardelyx's presentation please visit the Events & Presentations page within the Investor section of the Ardelyx website at [ir.ardelyx.com](https://ir.ardelyx.com). A replay of the webcast will be available on the Ardelyx website for 30 days following the event.

### About Ardelyx, Inc.

Ardelyx was founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs. Ardelyx's first approved product, IBSRELA® (tenapanor) is available in the United States and Canada. Ardelyx is developing XPHOZAH® (tenapanor), a novel product candidate for the control of serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis who have had an inadequate response or intolerance to phosphate binder therapy, which has completed three successful Phase 3 trials and an additional two Phase 4 open label trials. Ardelyx has a Phase 2 potassium lowering compound, RDX013, for the potential treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease and an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD. Ardelyx has established agreements with Kyowa Kirin in Japan, Fosun Pharma in China and Knight Therapeutics in Canada for the development and commercialization of tenapanor in their respective territories. For more information, please visit <https://ardelyx.com/> and connect with us on [X \(Formerly Twitter\)](#), [LinkedIn](#) and [Facebook](#).

### Investor and Media Contacts:

Caitlin Lowie  
[clowie@ardelyx.com](mailto:clowie@ardelyx.com)

Kimia Keshbod  
[kkeshbod@ardelyx.com](mailto:kkeshbod@ardelyx.com)



Source: Ardelyx, Inc.